Verstovsek Srdan, Vannucchi Alessandro M, Griesshammer Martin, Masszi Tamas, Durrant Simon, Passamonti Francesco, Harrison Claire N, Pane Fabrizio, Zachee Pierre, Kirito Keita, Besses Carlos, Hino Masayuki, Moiraghi Beatriz, Miller Carole B, Cazzola Mario, Rosti Vittorio, Blau Igor, Mesa Ruben, Jones Mark M, Zhen Huiling, Li Jingjin, Francillard Nathalie, Habr Dany, Kiladjian Jean-Jacques
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Italy.
Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21.
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analysis occurred when all patients completed the Week 80 visit or discontinued. Objectives included evaluating the durability of the primary response (Week 32 phlebotomy-independent hematocrit control plus ≥35% spleen volume reduction), its components, and that of complete hematologic remission; and long-term safety. Median exposure was 111 weeks; 91/110 (82.7%) patients randomized to ruxolitinib remained on treatment. No patients continued best available therapy (98/112 [87.5%] crossed over to ruxolitinib, most at/soon after Week 32). At Week 32, primary response was achieved by 22.7% vs. 0.9% of patients randomized to ruxolitinib and best available therapy, respectively (hematocrit control, 60.0% vs. 18.8%; spleen response, 40.0% vs. 0.9%). The probability of maintaining primary and hematocrit responses for ≥80 weeks was 92% and 89%, respectively; 43/44 spleen responses were maintained until Week 80. Complete hematologic remission at Week 32 was achieved in 23.6% of ruxolitinib-randomized patients; the probability of maintaining complete hematologic remission for ≥80 weeks was 69%. Among ruxolitinib crossover patients, 79.2% were not phlebotomized, and 18.8% achieved a ≥35% reduction from baseline in spleen volume after 32 weeks of treatment. New or worsening hematologic laboratory abnormalities in ruxolitinib-treated patients were primarily grade 1/2 decreases in hemoglobin, lymphocytes, and platelets. The thromboembolic event rate per 100 patient-years was 1.8 with randomized ruxolitinib treatment vs. 8.2 with best available therapy. These data support ruxolitinib as an effective long-term treatment option for hydroxyurea-resistant or intolerant patients with polycythemia vera. This trial was registered at clinicaltrials.gov identifier: 01243944.
RESPONSE是一项开放标签的3期研究,评估JAK1/JAK2抑制剂鲁索替尼与最佳可用疗法相比,对羟基脲耐药或不耐受的真性红细胞增多症患者的疗效和安全性。这项预先计划的分析在所有患者完成第80周访视或停药时进行。目标包括评估主要缓解(第32周不依赖放血的血细胞比容控制加脾脏体积减少≥35%)的持久性、其组成部分以及完全血液学缓解的持久性;以及长期安全性。中位暴露时间为111周;随机分配至鲁索替尼组的110例患者中有91例(82.7%)继续接受治疗。没有患者继续接受最佳可用疗法(112例中有98例[87.5%]交叉接受鲁索替尼治疗,大多数在第32周时或之后不久)。在第32周时,随机分配至鲁索替尼组和最佳可用疗法组的患者中,主要缓解率分别为22.7%和0.9%(血细胞比容控制率分别为60.0%和18.